Page 7 - Interim Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent ... SpringWorks Therapeutics, Inc.February 25, 2021 GMT - Reported Interim Data from Phase 2b ReNeu Trial of Mirdametinib in NF1-PN Demonstrating Encouraging Clinical Activity and Tolerability in the First 20 Adult Patients Enrolled - -  - Continued to Strengthen Nirogacestat Patent Portfolio - - Multiple Data Readouts Expected in 2021 Across Pipeline, Including Topline Data from Phase 3 DeFi Trial in ...

1 / of 2 COVID-19 vaccine from China's Sinovac 91.25 per cent effective, Turkey says after trial involving 7,000 volunteers Posted ThuThursday 24 DecDecember 2020 at 11:03pm CoronaVac vaccine, made by Sinovac, is currently on phase 3 clinical trials at Acibadem Hospital in Istanbul. ( Print text only Cancel A COVID-19 vaccine developed by China's Sinovac Biotech has been 91.25 per cent effective, according to interim data from a late-stage trial in Turkey, a potentially much better result than reported from a separate trial of the vaccine in Brazil. Key points: Common adverse effects caused ...